Edgar Haber

US Patent:

6576431, Jun 10, 2003

Filed:

Aug 16, 2001

Appl. No.:

09/930307

Inventors:

Guy L. Reed - Winchester MA
Edgar Haber - Salisbury NH
Gary R. Matsueda - Princeton NJ

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

G01N 3353

US Classification:

435 71, 435 792, 435 13, 436501, 436512, 436513

Abstract:

The present invention relates to a treatment for myocardial infarction and blood clots within a patient, and more specifically to a therapy which enhances clot lysis comprising administering to a patient an antibody directed to 2-antiplasmin crosslinked to fibrin (2AP-FX) which does not inhibit plasma 2-antiplasmin (2AP). The invention also relates to a treatment for enhancing clot lysis comprising administering an antibody directed toward 2-antiplasmin crosslinked to fibrin which does not inhibit plasma 2AP together with a thrombolytic agent.

US Patent:

20090012020, Jan 8, 2009

Filed:

Jun 4, 2007

Appl. No.:

11/810344

Inventors:

Mu-En Lee - Newton MA, US
Mei Lee - Newton MA, US
Edgar Haber - Salisbury NH, US
Carol Haber - Salisbury NH, US
Mark A. Perrella - Brookline MA, US
Gokhan S. Hotamisligil - Cambridge MA, US

International Classification:

A61K 31/711
A61P 9/10

US Classification:

514 44

Abstract:

The invention features a method of inhibiting formation of atherosclerotic lesions by administering to a mammal, e.g., a human patient who has been identified as suffering from or at risk of developing atherosclerosis, a compound that reduces expression or activity of AFABP.

US Patent:

52564134, Oct 26, 1993

Filed:

Sep 15, 1992

Appl. No.:

7/946015

Inventors:

Edgar Haber - Weston MA
Gary R. Matsueda - Winchester MA

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 39395
C07K 1528

US Classification:

424 858

Abstract:

Disclosed is a method for the in vivo lysis of a thrombus in a host by administration of a conjugate consisting of a monoclonal antibody specific for fibrin coupled to a plasminogen activator such as tissue plasminogen activator, urokinase or streptokinase.

US Patent:

51166135, May 26, 1992

Filed:

Jan 8, 1985

Appl. No.:

6/689851

Inventors:

Edgar Haber - Weston MA
Gary R. Matsueda - Winchester MA

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 39395
C07K 1528

US Classification:

424 858

Abstract:

A thrombolytic product comprising a fibrin-specific antibody substantially devoid of fibrinogen cross-reactivity coupled to a thrombolytic agent.

US Patent:

53728122, Dec 13, 1994

Filed:

Sep 10, 1992

Appl. No.:

7/943372

Inventors:

Guy L. Reed - Cambridge MA
Gary R. Matsueda - Princeton NJ
Edgar Haber - New York NY

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 3754
A61K 37547
A61K 3900
C07K 1528

US Classification:

4241451

Abstract:

The present invention relates to a novel treatment for blood clots within a patient or myocardial infarction which comprises administering a hapten-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for blood clots within a patient or myocardial infarction comprising coadministrating the hapten-binding molecule of the invention together with a thrombolytic agent capable of either dissolving fibrin-platelet clots or inhibiting their formation. The therapy of the invention is capable of increasing clot lysis while minimizing fibrinogen breakdown and preventing the reocclusion of the affected coronary artery. The therapy of the present invention is capable of achieving this goal even in the absence of heparin and when the concentration of thrombolytic agent is lower than that required by other potential therapies.

US Patent:

56098693, Mar 11, 1997

Filed:

May 30, 1995

Appl. No.:

8/453779

Inventors:

Thomas Quertermous - Nashville TN
Marschall S. Runge - Atlanta GA
Edgar Haber - Salisbury NH

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 39395

US Classification:

4241331

Abstract:

Hybrid immunoglobulin-enzyme molecules are provided which are composed of antibodies, or derivatives or fragments thereof, which specifically bind an arterial or venous thrombus that are operably linked to the enzymatically active portions of thrombolytic enzymes such as plasminogen activators. In a preferred embodiment the hybrid molecules specifically bind to fibrin and have fibrinolytic activity. The hybrid molecules of the present invention may be produced by any means, including chemical conjugation, or by means of recombinant DNA, genetic engineering and/or hybridoma technology. Methods for making and using the molecules in diagnosis and therapy are also disclosed.

US Patent:

61369535, Oct 24, 2000

Filed:

Apr 2, 1998

Appl. No.:

9/054298

Inventors:

Mu-En Lee - Newton MA
Edgar Haber - Salisbury NH
Mukesh Jain - West Newton MA

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

C07K 14435

US Classification:

530350

Abstract:

A substantially pure DNA comprising a sequence encoding a smooth muscle cell LIM (SmLIM) polypeptide, methods of diagnosing vascular injury by detecting a decrease in SmLIM gene expression, and methods of inhibiting vascular smooth muscle cell proliferation.

US Patent:

55715230, Nov 5, 1996

Filed:

Mar 9, 1995

Appl. No.:

8/401341

Inventors:

Mu-En Lee - Newton MA
Edgar Haber - Salisbury NH
Jer-Chia Tsai - Kaohsiung, TW

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

A61F 202

US Classification:

424423

Abstract:

A method of inhibiting arteriosclerosis or smooth muscle cell proliferation by identifying an animal having an artery suspected of needing such inhibition and contacting the artery with an apoptosis-inducing amount of an antioxidant.